Navigation Links
Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
Date:12/20/2007

CAMBRIDGE, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview, including an update of the company's HCV and HIV discovery and development programs, at the upcoming JP Morgan 26th Annual Healthcare Conference on Tuesday, January 8, 2008 at 2:30 p.m. PT at the Westin St. Francis Hotel in San Francisco.

The live and archived webcasts of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived replay will be available on the Idenix website for two weeks following the conference.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)... WASHINGTON, Aug. 29 /PRNewswire-USNewswire/ -- Th...onsistent procedures to allow the public to,see ex...ished today in the,Federal Register http://edocke...will ensure that the best and latest available evi... risk assessments for health,standards regulating ...
(Date:8/29/2008)...iation may have caused chromosomal change that rai... FRIDAY, Aug. 29 (HealthDay News) -- Some Japanese...in Hiroshima and Nagasaki experienced key genetic ...of thyroid cancer, new research indicates. , Pa...o a particular genetic mutation involving the so-c...
(Date:8/29/2008)... LEEDS, England, August 29 /PRNewswire/ --, - MYA...ce for Recent,Big Brother Stars but the big Questi...as, mirrors all around and being on national,telev...ct on how you feel,about the way you look. For man... a reality. Upon leaving the house contestants may...
(Date:8/29/2008)... Dr. Milton Owens and the Co... Southern California to provide protection for cas...on, and the Hispanic community is benefiting. , ...ust 29, 2008 -- Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin...
Breaking Medicine News(10 mins):Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2
... to a survey, mental health wards have been graded... mental health inpatients//. The charity called M...ction over the state of repair of their ward while...ndards of hygiene.Mind is for patients to be treat...
... a voluntary organization helping with the necessi...C), Thiruvananthapuram//. To mark its tenth anniv...ir on Wednesday. He handed over a copy of the souv...n.Mr. Bhatia, who applauded the services provided ...
...ients with schizophrenia whose medication is chang...cts, second-generation// antipsychotic drugs do no... first-generation antipsychotic drugs, according t...ves of General Psychiatry, one of the JAMA/Archive...
...has moles. Most of the time, they are nothing but ...ng cells in moles called melanocytes// start divid...r called melanoma. About one in 65 Americans born ...oma at some point during their lifetime. Scientist...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:A decade of service to cancer patients 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3
(Date:8/26/2008)...stCall/ -- XTENT, Inc.,(Nasdaq: XTNT ) today anno...om the CUSTOM II trial was published in the most r...rvention. The lead author of the article was,Dr. P...r Utrecht, Utrecht,The Netherlands on behalf of t...across Europe., The one-year CUSTOM II trial, a s...
(Date:8/25/2008).../ -- Joseph F. Finn, Jr.,C.P.A. ("Finn"), Assigne...,the benefit of creditors, announced today that al...d at a sealed bid auction on October 10,2008., S...opa-Carbidopa that,is the current gold standard tr... estimated at approximately $250 million. Signific...
(Date:8/22/2008)..., - Dangerous Bacteria Infect Three Million Peopl...tried can also be innovative: already in,Ancient G...ial. This,ability is now playing an important role... In a worldwide noted field test, a whole hospital...rg, Germany, was equipped with,door handles, door ...
(Date:8/21/2008)...tial in independent study of ad...g. 21 /- A recently published article...ation has expanded our,understanding of the clinic...in adult patients at risk for organ rejection or i...ablo Sanchez-Velasco and his colleagues in the Can...
Breaking Medicine Technology:XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 2Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test 3New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 2New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation 3Commonwealth Fund Commission issues reform recommendations for next president 6383 1Commonwealth Fund Commission issues reform recommendations for next president 6383 2Commonwealth Fund Commission issues reform recommendations for next president 6383 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 1FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 2FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 3FDA Hears Pros Cons of Pharmacist to Patient Drug Sales 6381 4BIO key Reports Third Quarter 2007 Results 1228 1BIO key Reports Third Quarter 2007 Results 1228 2BIO key Reports Third Quarter 2007 Results 1228 3BIO key Reports Third Quarter 2007 Results 1228 4BIO key Reports Third Quarter 2007 Results 1228 5Predicting the future in ovarian cancer 6379 1Predicting the future in ovarian cancer 6379 2
...USINESS WIRE)--Jun 7, 2007 - Clinical results from...the American,Headache Society (AHS) annual meeting...itonin gene-related peptide (CGRP),receptor antago...two hours after dosing compared to placebo, and th...as generally well tolerated in,the study. Response...
... 900-mcg dosed every two weeks achieved an SVR rat...(ITT analysis), with,more favorable quality-of-lif...ire-FirstCall/ -- Human,Genome Sciences, Inc. toda...2b clinical trial of Albuferon(R) (albinterferon a...-naive patients with,genotype 1 chronic hepatitis ...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...ssional Diagnostics is a leading provider of immun...A test menu that includes kits for autoimmune dise...ellaneous conjugates and components. Our Impact IF...rates and kit sizes to choose from. Kit components...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
...us disease ELISA products make us a leader in this...ntegration into the busy laboratory, our Infectiou...lity and run-to-run consistency. Our Infectious Di...s for a wide range of serological assays including...
Medicine Products: